Max Healthcare Institute (MAXHEALTH) has faced sustained downside from July 2025 highs due to valuation concerns and technical weakness, but today’s intraday upside reflects oversold rebound and short-covering without specific news triggers. Detailed technicals show neutral bias with support holds; fundamentals strong on expansions amid macro healthcare tailwinds.
Technical Analysis:
Current price ~₹1027.70 (Jan 8 close, -0.68% but intraday recovery from ₹1024 low), down 22% from ATH ₹1314; below 50DMA ₹1083, 100DMA ₹1095, 200DMA ₹1074 signaling bearish short-term trend.
RSI(14) 48 (neutral), STOCH 30 (oversold sell), MACD -2.12 (sell), CCI -100 (sell); oscillators neutral (5 neutral/3 sell), MAs mixed (5 buy/7 sell), overall neutral rating with ATR 10.47 low volatility.
Key levels: Pivot ₹1073, Support S1 ₹1070/S2 ₹1066/S3 ₹1064, Resistance R1 ₹1076/R2 ₹1080/R3 ₹1082; volume 10.6L shares (avg 12.7L), beta 0.92 suggests outperformance potential on breakout.
Fundamental Analysis:
FY25 rev ₹7941 Cr (+13%), net ₹1357 Cr (+29%), EBITDA ₹523 Cr (26% margin +35% YoY) driven by ARPOB ₹58k (+10%), occupancy 75-80%, 5143 beds operational.
Balance sheet solid: Debt/Equity 0.19, ROE 13.9% (up from 10%), ROCE 16.5%, cash ₹1200 Cr; P/E 74x fwd (premium), EV/EBITDA 45x but justified by 21% rev CAGR FY24-27 est., ROIC 14%>WACC.
Growth levers: 1000+ beds addition FY26 (Mohali, Nanavati, Pune), diagnostics 10% rev mix, international 15%; promoter 23.7%, FII 54.8% stake.
Downfall & Today’s Upside Reasons:
Lagataar downfall Sep-Dec 2025 from MA breakdowns, put-heavy OI (bearish), delivery drop (-31%), sector rotation, downside targets ₹940 amid high P/E critique.
Aaj positive move (intraday +0.3% bounce) from oversold STOCH/RSI, short-covering near S3 ₹1064, VWAP ₹1028 buying; no news but 7-day +5% momentum resumption.
Micro & Macro View:
Micro: Short-term neutral-buy on support hold ₹1024, Q3 rev est. ₹2600 Cr key; 5-8% upside to R3 if RSI>50, SL ₹1060.
Macro: Bullish; healthcare mkt ₹40T by 2030 (15% CAGR), insurance 50% penetration, aging population, Max’s metro premiumization (25% margins) positions for 20%+ PAT CAGR.
Upcoming Events & Impact:
Q3FY26 results (late Jan 2026): Consensus rev ₹2620 Cr (+18%), PAT ₹378 Cr (+20%); beat on occupancy/ARPOB lifts 10-15% rally, miss pressures to ₹950.
JHL/CRL merger closure (Q1CY26), CGHS rate hike (₹200 Cr FY27 rev), Pune land FY26 phased; positive catalysts for 1000 beds, EPS accretion ~5%.
Disclaimer:
This report is for informational/educational purposes only and does not constitute financial advice, buy/sell recommendation, or investment solicitation. Markets involve risks; past results ≠ future performance. Consult qualified advisor, perform own analysis. Investogainer Research or associates disclaim liability for decisions based hereon.